Evidence map›Paper›PMID 39142837›Full record

ArticleBMJ case reports2024

Effective and safe use of intramuscular clozapine in a patient presenting with catatonia and thrombocytopenia.

Suresh Thapaliya, Eromona Whiskey, Mudasir Firdosi

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Involuntary Clozapine Treatment: A Systematic Review.Acta psychiatrica Scandinavica · 2026
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Suresh ThapaliyaKent and Medway NHS and Social Care Partnership Trust, Maidstone, UK.
Eromona WhiskeyKent and Medway NHS and Social Care Partnership Trust, Maidstone, UK.
Mudasir FirdosiKent and Medway NHS and Social Care Partnership Trust, Maidstone, UK mudasirfirdosi@gmail.com.ORCID http://orcid.org/0000-0002-8450-6484

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clozapine is the most effective medication for the management of treatment-resistant schizophrenia and schizoaffective disorder, and its discontinuation can pose significant challenges in treatment. We present a patient with a diagnosis of schizoaffective disorder who was stable on clozapine for a decade until discontinuation due to thrombocytopenia. She experienced a relapse of her illness, presenting with psychotic and catatonic features with poor oral intake and physical health complications requiring a lengthy admission to the hospital. There was a poor response to alternative antipsychotics and a full course of electroconvulsive therapy. Intramuscular (IM) clozapine was initiated due to catatonia and refusal to accept oral medications. After receiving 10 doses of IM clozapine, she started accepting oral clozapine and made a full recovery within a few weeks. The low platelet count was persistent, and a bone marrow biopsy showed results consistent with immune thrombocytopenia being the cause of that low platelet count.

Indexed as

Antipsychotic AgentsCatatoniaClozapineThrombocytopeniaFemaleHumansInjections, IntramuscularPsychotic DisordersTreatment OutcomeAntipsychotic AgentsClozapineEthicsHaematology (drugs and medicines)Haematology (incl blood transfusion)ImmunologyPsychiatry (drugs and medicines)

Identifiers

PMID39142837
PMCPMC12451906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.